Amsterdam, NL – Dispertech B.V., a deeptech startup in the field of nanoparticle analysis instruments and solutions, has received an investment from a consortium of investors led by Value Creation Capital.

Dispertech’s products enable researchers in the field of life science and healthcare to measure size, refractive index, and concentration of biological nanoparticles, including extracellular vesicles, viruses, lipid-nanoparticles, nanomedicine and RNA-vaccines. Biological nanoparticles is an important and fast growing field of research with high potential in both diagnostic and therapeutic applications.

The investment will enable Dispertech to accelerate its sales effort, scale up its organisation, and strengthen its leading position in the scientific market. Furthermore, the investment allows Dispertech to implement an ambitious innovation program for the development of nanoparticle analysis technology for the next generation of products.

Hans Brouwer, CEO of Dispertech comments: “We are thrilled to receive the trust of Value Creation Capital. Their investment and venture support will enable us to realise our growth ambitions.”

Willem van den Berg, Managing Partner of Value Creation Capital comments: “We are excited to invest in this interesting Deep Tech nanoparticle detection domain and enabling further growth of Dispertech.”